Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13102204 | 0.92 | ALDH1A1 (0.61) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101632 | 0.90 | ALDH1A1 (0.52) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101644 | 0.89 | ALDH1A1 (0.49) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101952 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101965 | 0.88 | ALDH1A1 (0.56) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101641 | 0.88 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101698 | 0.86 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13102068 | 0.86 | RAB9A (0.51) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13101963 | 0.86 | ALDH1A1 (0.58) | ALDH1A1LMNAHTTMEN1KMT2A | |
| SCHEMBL13282913 | 0.85 | NPSR1 (0.61) | ALDH1A1LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329713-B2 | Fused ring heterocycles as potassium channel modulators | ICAGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | ICAGEN, INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273784-A1 | FUSED RING HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS | KCNK17, KCNJ2, KCNJ1 | ALDH1A1 2354/4885LMNA 1121/4885HTT 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.